Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review
- PMID: 33042552
- PMCID: PMC7534595
- DOI: 10.1016/j.nmni.2020.100776
Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review
Abstract
Hydroxychloroquine (HCQ) has shown efficacy against coronavirus disease 2019 (COVID-19) in some but not all studies. We hypothesized that a systematic review would show HCQ to be effective against COVID-19, more effective when provided earlier, not associated with worsening disease and safe. We searched PubMed, Cochrane, Embase, Google Scholar and Google for all reports on HCQ as a treatment for COVID-19 patients. This included preprints and preliminary reports on larger COVID-19 studies. We examined the studies for efficacy, time of administration and safety. HCQ was found to be consistently effective against COVID-19 when provided early in the outpatient setting. It was also found to be overall effective in inpatient studies. No unbiased study found worse outcomes with HCQ use. No mortality or serious safety adverse events were found. HCQ is consistently effective against COVID-19 when provided early in the outpatient setting, it is overall effective against COVID-19, it has not produced worsening of disease and it is safe.
Keywords: Azithromycin; COVID-19; SARS-CoV-2; hydroxychloroquine; outpatient.
© 2020 The Authors.
Similar articles
-
Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.J Infect Chemother. 2021 Jun;27(6):882-889. doi: 10.1016/j.jiac.2021.02.021. Epub 2021 Feb 22. J Infect Chemother. 2021. PMID: 33678548 Free PMC article.
-
The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.Can Respir J. 2020 Oct 13;2020:4312519. doi: 10.1155/2020/4312519. eCollection 2020. Can Respir J. 2020. PMID: 33082891 Free PMC article.
-
COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.Pain Physician. 2020 Aug;23(4S):S351-S366. Pain Physician. 2020. PMID: 32942793 Review.
-
Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.J Med Virol. 2020 Jul;92(7):776-785. doi: 10.1002/jmv.25898. Epub 2020 May 3. J Med Virol. 2020. PMID: 32297988 Free PMC article.
-
Hydroxychloroquine is protective to the heart, not harmful: a systematic review.New Microbes New Infect. 2020 Sep;37:100747. doi: 10.1016/j.nmni.2020.100747. Epub 2020 Aug 20. New Microbes New Infect. 2020. PMID: 32839670 Free PMC article. Review.
Cited by
-
Potential of traditional medicines in alleviating COVID-19 symptoms.Front Pharmacol. 2024 Sep 26;15:1452616. doi: 10.3389/fphar.2024.1452616. eCollection 2024. Front Pharmacol. 2024. PMID: 39391697 Free PMC article. Review.
-
Increased red cell distribution width predicts mortality in COVID-19 patients admitted to a Dutch intensive care unit.Acute Crit Care. 2024 Aug;39(3):359-368. doi: 10.4266/acc.2023.01137. Epub 2024 Aug 22. Acute Crit Care. 2024. PMID: 39266271 Free PMC article.
-
The effect of oral hydroxychloroquine on chondral defect: An experimental study.Jt Dis Relat Surg. 2023 Aug 21;34(3):628-639. doi: 10.52312/jdrs.2023.1114. Jt Dis Relat Surg. 2023. PMID: 37750268 Free PMC article.
-
Co-infection of COVID-19 and parasitic diseases: A systematic review.Parasite Epidemiol Control. 2023 May;21:e00299. doi: 10.1016/j.parepi.2023.e00299. Epub 2023 Mar 30. Parasite Epidemiol Control. 2023. PMID: 37091061 Free PMC article. Review.
-
Consumption Trends of Antibiotics in Brazil During the COVID-19 Pandemic.Front Pharmacol. 2022 Mar 21;13:844818. doi: 10.3389/fphar.2022.844818. eCollection 2022. Front Pharmacol. 2022. PMID: 35387351 Free PMC article.
References
-
- Guérin V., Lévy P., Thomas J.L., Lardenois T., Lacrosse P., Sarrazin E. Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/moderate COVID-19. Asian J Med Health. 2020;18:45–55.
-
- Cavalcanti A.B., Zampieri F.G., Azevedo L.C., Rosa R.G., Avezum A., Veiga V.C. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medRxiv. 2020
-
- Zelenko V. 23 March 2020. Open letter describing Covid-19 treatment protocol.http://www.nunesfarma.com.br/download.php?id=TlRBPQ== Available at:
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous